JPMorgan upgraded Recursion Pharmaceuticals (RXRX) to Overweight from Neutral with a price target of $11, up from $10. The firm says the company’s ...
GUILDFORD, SURREY / ACCESSWIRE / September 19, 2024 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in ...
Exscientia Plc (EXAI) has released an update. Exscientia plc has entered into a definitive agreement for acquisition by Recursion Pharmaceuticals, with the transaction aimed at combining their ...
SALT LAKE CITY - Recursion, empresa de TechBio en fase clínica, ha dado a conocer los resultados preliminares del ensayo de fase 2 SYCAMORE con REC-994, un fármaco candidato para tratar la ...
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX), con sede en Salt Lake City, ha obtenido un compromiso irrevocable de Evotec SE, accionista significativo de Exscientia plc, para apoyar la adquisición ...
On Thursday, Exscientia plc (NASDAQ:EXAI) agreed to merge with Recursion Pharmaceuticals Inc. (NASDAQ:RXRX). Exscientia shareholders will receive 0.7729 Recursion shares for each Exscientia share, ...
Recursion Pharmaceuticals (RXRX) shares rallied 13.8% in the last trading session to close at $12.43. This move can be attributable to notable volume with a higher number of shares being traded than ...
We recently compiled a list of the 35 Trending AI Stocks on Latest News and Analyst Ratings. In this article, we are going to take a look at where Exscientia plc (NASDAQ:EXAI) stands against the other ...
SALT LAKE CITY--(BUSINESS WIRE)--Recursion, a next-gen biopharma company combining automated, experimental biology with artificial intelligence to discover and develop drugs at scale, today announced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback